using the same AI model (uPath—Roche) demonstrated clinical relevance in a series of patients with advanced‐stage NSCLC previously treated with a single agent PD‐1/PD‐L1 checkpoint blockade. The gene discussed is CD274; the disease is non-small cell lung carcinoma.